Singapore markets closed

AbbVie Inc. (ABBV)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
118.33+0.79 (+0.67%)
As of 2:44PM EDT. Market open.
Sign in to post a message.
  • S
    Sabrina
    Muted Terry.
  • D
    DennisK
    I hope Abbvie doesn't make any big acquisition at this time. Pay off the debt so it can continue to increase dividends like they have. They are still digesting Allergan. Build that pipeline so it will be ready when Humira goes off patent
  • g
    gabriel
    What is the matter with this stock? It goes up or down with no news! And sometimes when it gets bad news it goes up and with good news it might go down…!
  • A
    Anonymous
    No big deal, Dow and Nasdaq had a beating. Nothing goes straight up so with ABBV. Last quarter sp was at $105+, now at $115+ that's $10 plus difference, and in few days it will back up. DIV pay day soon, with this correction, its a buying opportunity. Patience is what's need. Short gain pays more tax to Uncle Sam.
  • A
    Anonymous
    AbbVie Secures Breakthrough Therapy Designation for Venetoclax in Higher Risk Myelodysplastic Syndrome
    BY MT Newswires
    — 4:17 AM ET 07/21/2021
    04:17 AM EDT, 07/21/2021 (MT Newswires) -- AbbVie ( ABBV
    Loading...
    Loading...
    ) said Wednesday the US Food and Drug Administration has granted a breakthrough therapy designation for venetoclax in combination with azacitidine for adult patients with higher-risk myelodysplastic syndrome, a group of bone marrow disorders.

    The designation, which was the sixth breakthrough therapy status awarded to venetoclax, qualifies the drug for an expedited review process.

    Venetoclax is being developed under a collaboration between AbbVie ( ABBV
    Loading...
    Loading...
    ) and Roche.

    Price: 116.05, Change: +0.63, Percent Change: +0.55
  • B
    Brendan
    Distinguishing a professional broker is one of the criteria that's required in an online investment that's why i would recommend only one legit platform that's trustworthy and reliable.
  • C
    Chiquito
    Terry muted
  • J
    JOHNNY
    Of all the positions in my portfolio ABBV had the highest % loss.
    I still think this stock is a good play. Guess I will find out on July 30th.
  • S
    Sabrina
    Target Price moves up...Hang on to our shares folks..GLTA

    AbbVie (NYSE:ABBV) Reaches New 1-Year High at $118.35
    Posted by ABMN Staff on Jul 12th, 2021

    AbbVie logoAbbVie Inc. (NYSE:ABBV)’s share price hit a new 52-week high on Monday . The company traded as high as $118.35 and last traded at $117.62, with a volume of 123401 shares changing hands. The stock had previously closed at $116.58.

    A number of equities analysts have recently issued reports on ABBV shares. Piper Sandler increased their price objective on shares of AbbVie from $120.00 to $124.00 and gave the company an “overweight” rating in a research note on Friday, April 30th. Daiwa Capital Markets started coverage on shares of AbbVie in a research note on Friday, July 2nd. They issued an “outperform” rating for the company. BMO Capital Markets increased their price objective on shares of AbbVie from $127.00 to $129.00 and gave the company an “outperform” rating in a research note on Monday, May 3rd. Mizuho increased their price objective on shares of AbbVie from $126.00 to $128.00 and gave the company a “buy” rating in a research note on Monday, May 3rd. Finally, SVB Leerink increased their price objective on shares of AbbVie from $140.00 to $144.00 and gave the company an “outperform” rating in a research note on Tuesday, March 30th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the stock. AbbVie has a consensus rating of “Buy” and an average price target of $120.25.
  • S
    Sabrina
    Very nice to be at the $30's unrealized profit in few days only, parked with ABBV. 52 weeks high just around the corner, and DIV, just few steps ahead...that adds up. Ladies and Gents, we got Drugs in the Pipeline that are approved and more soon. IMO our investment are in the safe hands. Few more hours to BUY to get the $1.30 DIVIDEND...Ex Dividend Date July 14 and Recording Date July 15 the following Day...Onward we march ABBV.
  • A
    Anonymous
    You havent muted Terry yet ? 😂
  • A
    Anonymous
    Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting
    BY PR Newswire
    — 8:30 AM ET 07/20/2021
    NORTH CHICAGO, Ill., July 20, 2021 /PRNewswire/ -- Allergan, an AbbVie ( ABBV
    Loading...
    Loading...
    ) company, today announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) Annual Meeting being held July 23-27 in Las Vegas, NV. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an investigational presbyopia treatment, and updated analyses on DURYSTA™ (bimatoprost intracameral implant), the first and only FDA-approved dissolvable implant to reduce eye pressure in people with open angle glaucoma or high eye pressure.

    "As a company, we remain committed to advancing care for difficult-to-treat eye conditions and diseases, such as presbyopia and glaucoma, that have a profound impact on daily life for millions of people," said Michael R. Robinson, M.D., vice president, global therapeutic area head, eye care, AbbVie ( ABBV
    Loading...
    Loading...
    ). "Data presented at the 2021 ASCRS Annual Meeting will help us understand the potential for AGN-190584 to be a first-of-its-kind treatment option for those living with presbyopia, as well as augment our knowledge of DURYSTA, which has changed how physicians can care for patients with glaucoma."

    Researchers will present new data evaluating the efficacy, safety and tolerability of investigational AGN-190584 for the treatment of presbyopia, inclusive of full data results from the Phase 3 GEMINI 1 study. GEMINI 1 data, in combination with data from the GEMINI 2 study, formed the basis of the AGN-190584 New Drug Application (NDA) currently under review with the U.S. Food and Drug Administration, which the agency is expected to act on by the end of 2021.

    Updated analyses from the Phase 3 ARTEMIS studies assessing the efficacy and duration of DURYSTA will also be presented. DURYSTA was approved by the FDA in March 2020 to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma (OAG) or high eye pressure (ocular hypertension, or OHT). Allergan has continued to collect data to further understand how DURYSTA can best be used to benefit patients living with glaucoma.
  • T
    Terry
    Frantic selling of ABT and ABBV after hours.....anybody know anything ...
  • J
    Joe
    yowza- YTD & 52wk. high today, approaching all time high, with a div locked down.. up >100% in 2 yrs. with divs- not too shabby %^)
  • D
    David
    Yahoo changed their app. Where is the Target Price?
  • a
    avni
    it is not worth buying the stock for the dividend , abbv dividend after today is 1.30 per share so today it is losing the same amount per share , so where is the benefit of the dividend ?
  • S
    Sabrina
    Good read...think about it. I quote !!!!
    " AbbVie
    AbbVie’s stock is up 7.4% this year so far. Estimates for 2021 earnings have increased from $12.59 to $12.60 per share in the past 60 days while that for 2022 have risen from $13.96 to $14.00 over the same period

    AbbVie has been successful in expanding labels of its cancer drugs, Imbruvica and Venclexta. AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta, which have become key contributors to sales growth.

    Its two new immunology drugs, Skyrizi and Rinvoq, are also performing beyond expectations. With many new indications coming in the next couple of years, sales of these drugs could be higher and have the potential to replace Humira when generics are launched in 2023.

    It has an impressive late-stage pipeline with several early/mid-stage candidates that have blockbuster potential. AbbVie expects approval of more than a dozen new products/line extensions for major indications over the next two years, which can collectively add meaningful revenue growth in advance of the U.S. Humira loss of exclusivity in 2023. " end of quote.
  • T
    Terry
    Social European model infrastructure has big Pharma footing the bill amongst others....no wonder many drugcos located in Ireland, Switzerland, and USA.....
  • G
    Greg
    Should I be concerned ARKG has been selling some every day?
  • J
    JoeBlack
    Terry,

    What’s your deal? You can’t possibly own Abbvie with your negative attitude toward the company so why be on here?